Fusion Antibodies plc (LSE:FAB) has secured a contract for a humanisation project with the US subsidiary of a global pharmaceutical group. While the deal is expected to deliver modest revenues, it is strategically important as it demonstrates Fusion’s ability to attract large-scale pharmaceutical partners, reducing its dependence on smaller clients. The project is scheduled for completion within the current financial year and further underscores the company’s expertise in therapeutic antibody development.
Despite the positive contract news, Fusion continues to face significant financial headwinds, including declining revenues, heavy losses, and negative valuation indicators. Technical analysis reflects a bearish trend, though recent fundraising efforts and collaborations suggest potential opportunities for future recovery.
About Fusion Antibodies plc
Based in Belfast, Fusion Antibodies plc is a contract research organization specializing in antibody engineering for therapeutic and diagnostic use. Founded in 2001 as a spin-out from Queen’s University Belfast, the company provides services ranging from antibody generation and optimization to production and characterization. Fusion counts eight of the world’s top ten pharmaceutical companies among its clients, leveraging cutting-edge technologies to accelerate drug development.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply